1
|
Taylor MD, Gokgoz N, Andrulis IL, Mainprize TG, Drake JM, Rutka JT. Familial posterior fossa brain tumors of infancy secondary to germline mutation of the hSNF5 gene. Am J Hum Genet 2000; 66:1403-6. [PMID: 10739763 PMCID: PMC1288204 DOI: 10.1086/302833] [Citation(s) in RCA: 141] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2000] [Indexed: 01/31/2023] Open
Abstract
We have identified a family afflicted over multiple generations with posterior fossa tumors of infancy, including central nervous system (CNS) malignant rhabdoid tumor (a subset of primitive neuroectodermal tumors, or PNET) and choroid plexus carcinoma. Various hereditary tumor syndromes, including Li-Fraumeni syndrome, Gorlin syndrome, and Turcot syndrome, have been linked to increased risk of developing CNS PNETs and choroid plexus tumors. Malignant rhabdoid tumors of the CNS and kidney show loss of heterozygosity at chromosome 22q11. The hSNF5 gene on chromosome 22q11 has recently been identified as a candidate tumor-suppressor gene in sporadic CNS and renal malignant rhabdoid tumors. We describe a family in which both affected and some unaffected family members were found to have a germline splice-site mutation of the hSNF5 gene, leading to exclusion of exon 7 from the mature cDNA and a subsequent frameshift. Tumor tissue shows loss of the wild-type hSNF5 allele, in keeping with a tumor-suppressor gene. These findings suggest that germline mutations in hSNF5 are associated with a novel autosomal dominant syndrome with incomplete penetrance that predisposes to malignant posterior fossa brain tumors in infancy.
Collapse
Affiliation(s)
- Michael D. Taylor
- Arthur and Sonia Labatt Brain Tumor Research Centre, Division of Neurosurgery, Hospital for Sick Children, University of Toronto, Division of Neurosurgery, University of Toronto, and Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto
| | - Nalan Gokgoz
- Arthur and Sonia Labatt Brain Tumor Research Centre, Division of Neurosurgery, Hospital for Sick Children, University of Toronto, Division of Neurosurgery, University of Toronto, and Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto
| | - Irene L. Andrulis
- Arthur and Sonia Labatt Brain Tumor Research Centre, Division of Neurosurgery, Hospital for Sick Children, University of Toronto, Division of Neurosurgery, University of Toronto, and Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto
| | - Todd G. Mainprize
- Arthur and Sonia Labatt Brain Tumor Research Centre, Division of Neurosurgery, Hospital for Sick Children, University of Toronto, Division of Neurosurgery, University of Toronto, and Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto
| | - James M. Drake
- Arthur and Sonia Labatt Brain Tumor Research Centre, Division of Neurosurgery, Hospital for Sick Children, University of Toronto, Division of Neurosurgery, University of Toronto, and Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto
| | - James T. Rutka
- Arthur and Sonia Labatt Brain Tumor Research Centre, Division of Neurosurgery, Hospital for Sick Children, University of Toronto, Division of Neurosurgery, University of Toronto, and Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto
| |
Collapse
|
2
|
Sévenet N, Sheridan E, Amram D, Schneider P, Handgretinger R, Delattre O. Constitutional mutations of the hSNF5/INI1 gene predispose to a variety of cancers. Am J Hum Genet 1999; 65:1342-8. [PMID: 10521299 PMCID: PMC1288286 DOI: 10.1086/302639] [Citation(s) in RCA: 294] [Impact Index Per Article: 11.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023] Open
Abstract
Biallelic, truncating mutations of the hSNF5/INI1 gene have recently been documented in malignant rhabdoid tumor (MRT), one of the most aggressive human cancers. This finding suggests that hSNF5/INI1 is a new tumor-suppressor gene for which germline mutations might predispose to cancer. We now report the presence of loss-of-function mutations of this gene in the constitutional DNA from affected members but not from healthy relatives in cancer-prone families. Furthermore, a constitutional mutation is documented in a patient with two successive primary cancers. In agreement with the two-hit model, the wild-type hSNF5/INI1 allele is deleted in the tumor DNA from mutation carriers. In all tested cases, DNA from parents demonstrated normal hSNF5/INI1 sequences, therefore indicating the de novo occurrence of the mutation, which was shown to involve the maternal allele in one case and the paternal allele in two other cases. These data indicate that constitutional mutation of the hSNF5/INI1 gene defines a new hereditary syndrome predisposing to renal or extrarenal MRT and to a variety of tumors of the CNS, including choroid plexus carcinoma, medulloblastoma, and central primitive neuroectodermal tumor. This condition, which we propose to term "rhabdoid predisposition syndrome," may account for previous observations of familial and multifocal cases of the aforementioned tumor types. It could also provide the molecular basis for cases of Li-Fraumeni syndrome without p53 germline mutations.
Collapse
Affiliation(s)
- Nicolas Sévenet
- Laboratoire de Pathologie Moléculaire des Cancers, INSERM U 509, Institut Curie, Paris; Department of Clinical Genetics, St. James's University Hospital, Leeds; Pédiatrie Néonatale, Hôpital Caremeau, Nîmes, France; Pédiatrie et Génétique Médicale, Hôpital Charles Nicolle, Rouen; and Universität Kinderklinik, Tübingen, Germany
| | - Eammon Sheridan
- Laboratoire de Pathologie Moléculaire des Cancers, INSERM U 509, Institut Curie, Paris; Department of Clinical Genetics, St. James's University Hospital, Leeds; Pédiatrie Néonatale, Hôpital Caremeau, Nîmes, France; Pédiatrie et Génétique Médicale, Hôpital Charles Nicolle, Rouen; and Universität Kinderklinik, Tübingen, Germany
| | - Daniel Amram
- Laboratoire de Pathologie Moléculaire des Cancers, INSERM U 509, Institut Curie, Paris; Department of Clinical Genetics, St. James's University Hospital, Leeds; Pédiatrie Néonatale, Hôpital Caremeau, Nîmes, France; Pédiatrie et Génétique Médicale, Hôpital Charles Nicolle, Rouen; and Universität Kinderklinik, Tübingen, Germany
| | - Pascale Schneider
- Laboratoire de Pathologie Moléculaire des Cancers, INSERM U 509, Institut Curie, Paris; Department of Clinical Genetics, St. James's University Hospital, Leeds; Pédiatrie Néonatale, Hôpital Caremeau, Nîmes, France; Pédiatrie et Génétique Médicale, Hôpital Charles Nicolle, Rouen; and Universität Kinderklinik, Tübingen, Germany
| | - Rupert Handgretinger
- Laboratoire de Pathologie Moléculaire des Cancers, INSERM U 509, Institut Curie, Paris; Department of Clinical Genetics, St. James's University Hospital, Leeds; Pédiatrie Néonatale, Hôpital Caremeau, Nîmes, France; Pédiatrie et Génétique Médicale, Hôpital Charles Nicolle, Rouen; and Universität Kinderklinik, Tübingen, Germany
| | - Olivier Delattre
- Laboratoire de Pathologie Moléculaire des Cancers, INSERM U 509, Institut Curie, Paris; Department of Clinical Genetics, St. James's University Hospital, Leeds; Pédiatrie Néonatale, Hôpital Caremeau, Nîmes, France; Pédiatrie et Génétique Médicale, Hôpital Charles Nicolle, Rouen; and Universität Kinderklinik, Tübingen, Germany
| |
Collapse
|